{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:40:27Z","timestamp":1792701627259,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Livzon Pharmaceutical Group Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01722-5","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:22:38Z","timestamp":1792653758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic\/Pharmacodynamic Analysis of HHT120, a Novel Direct Thrombin Inhibitor, in Healthy Participants from a Phase I Clinical Trial"],"prefix":"10.1007","author":[{"given":"Qingyu","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runfeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9296-1873","authenticated-orcid":false,"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"1","key":"1722_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001155","volume":"9","author":"LE Flinterman","year":"2012","unstructured":"Flinterman LE, van Hylckama Vlieg A, Cannegieter SC, Rosendaal FR. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med. 2012;9(1):e1001155. https:\/\/doi.org\/10.1371\/journal.pmed.1001155.","journal-title":"PLoS Med"},{"issue":"2 Suppl","key":"1722_CR2","doi-asserted-by":"publisher","first-page":"e278S","DOI":"10.1378\/chest.11-2404","volume":"141","author":"Y Falck-Ytter","year":"2012","unstructured":"Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e278S-e325S. https:\/\/doi.org\/10.1378\/chest.11-2404.","journal-title":"Chest"},{"issue":"8","key":"1722_CR3","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.004","volume":"27","author":"DK Rose","year":"2018","unstructured":"Rose DK, Bar B. Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents. J Stroke Cerebrovasc Dis. 2018;27(8):2049\u201358. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2018.04.004.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"6","key":"1722_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/BF01073940","volume":"18","author":"JH Matis","year":"1990","unstructured":"Matis JH, Wehrly TE. Generalized stochastic compartmental models with Erlang transit times. J Pharmacokinet Biopharm. 1990;18(6):589\u2013607. https:\/\/doi.org\/10.1007\/BF01073940.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"4","key":"1722_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1517\/13543784.16.4.431","volume":"16","author":"AC Spyropoulos","year":"2007","unstructured":"Spyropoulos AC. Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs. 2007;16(4):431\u201340. https:\/\/doi.org\/10.1517\/13543784.16.4.431.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"1722_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2165\/11587290-000000000-00000","volume":"34","author":"S Schulman","year":"2011","unstructured":"Schulman S, Majeed A. A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. Drug Saf. 2011;34(6):449\u201363. https:\/\/doi.org\/10.2165\/11587290-000000000-00000.","journal-title":"Drug Saf"},{"issue":"4","key":"1722_CR7","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1097\/ALN.0b013e3181b437b1","volume":"111","author":"M Sigtermans","year":"2009","unstructured":"Sigtermans M, Dahan A, Mooren R, et al. S(+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. Anesthesiology. 2009;111(4):892\u2013903. https:\/\/doi.org\/10.1097\/ALN.0b013e3181b437b1.","journal-title":"Anesthesiology"},{"issue":"6","key":"1722_CR8","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/ALN.0b013e318218a881","volume":"114","author":"I Noppers","year":"2011","unstructured":"Noppers I, Olofsen E, Niesters M, et al. Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology. 2011;114(6):1435\u201345. https:\/\/doi.org\/10.1097\/ALN.0b013e318218a881.","journal-title":"Anesthesiology"},{"issue":"5","key":"1722_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34(5):711\u201326. https:\/\/doi.org\/10.1007\/s10928-007-9066-0.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"1722_CR10","first-page":"547","volume":"96","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost. 2006;96(5):547\u201352.","journal-title":"Thromb Haemost"},{"issue":"5","key":"1722_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9050445","volume":"9","author":"C Dunois","year":"2021","unstructured":"Dunois C. Laboratory monitoring of direct oral anticoagulants (DOACs). Biomedicines. 2021;9(5):445. https:\/\/doi.org\/10.3390\/biomedicines9050445.","journal-title":"Biomedicines"},{"issue":"6","key":"1722_CR12","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1160\/TH09-11-0758","volume":"103","author":"J van Ryn","year":"2010","unstructured":"van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116\u201327. https:\/\/doi.org\/10.1160\/TH09-11-0758.","journal-title":"Thromb Haemost"},{"issue":"1","key":"1722_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11239-014-1125-y","volume":"39","author":"M Samo\u0161","year":"2015","unstructured":"Samo\u0161 M, Stan\u010diakov\u00e1 L, Ivankov\u00e1 J, et al. Monitoring of dabigatran therapy using Hemoclot\u00ae. Thrombin inhibitor assay in patients with atrial fibrillation. J Thromb Thrombolysis. 2015;39(1):95\u2013100. https:\/\/doi.org\/10.1007\/s11239-014-1125-y.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"1722_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1046\/j.1365-2125.2001.01326.x","volume":"51","author":"M Cullberg","year":"2001","unstructured":"Cullberg M, Eriksson UG, Larsson M, Karlsson MO. Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease. Br J Clin Pharmacol. 2001;51(1):71\u20139. https:\/\/doi.org\/10.1046\/j.1365-2125.2001.01326.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1722_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1365-2125.2006.02667.x","volume":"62","author":"KH Liesenfeld","year":"2006","unstructured":"Liesenfeld KH, Sch\u00e4fer HG, Troc\u00f3niz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006;62(5):527\u201337. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02667.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1722_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/burnst\/tkaf004","volume":"13","author":"J Liu","year":"2025","unstructured":"Liu J, Zhang T, Luo X, et al. Rethinking universal anti-fibrinolysis: a randomized controlled trial on divergent fibrinolytic phenotypes in total knee arthroplasty. Burns Trauma. 2025;13:tkaf004. https:\/\/doi.org\/10.1093\/burnst\/tkaf004.","journal-title":"Burns Trauma."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01722-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:01:37Z","timestamp":1792699297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01722-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":16,"alternative-id":["1722"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01722-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xue Zhou, Jingyi Feng, Runfeng Lin, Yongxing Wang and Qin Huang are employees of Livzon Pharmaceutical Group Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the International Council for Harmonization Guidelines for Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants before any protocol-required procedures were performed.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study concept: QH and YZ; Data collection: RX, RFL and YXW; Data analysis: QYY, YOL, XZ and JYF; Writing, review and editing: QYY, XZ and YZ.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}